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The effect of dobutamine on exercise 
performance in patients with symptomatic 
ischemic heart disease 
The effect of dobutamine on exercise performance was assessed in 20 patients with ischemic 
heart disease (CAD) and a positive stress test. These patients had a wide range of resting left 
ventricular ejection fraction (range 22% to 6g%, mean 42%). Each patient entered a double-blind 
crossover study in which two identical exercise radionuclide ventriculograms were performed in 
patients on dobutamine, 5 Ag/kg/min intravenously, or placebo. Dobutamine increased resting 
left ventricular ejection fraction. Although ejection fraction fell with dobutamine during 
submaximal exercise, it remained higher than with placebo. At peak exercise, ejection fraction 
fell to the same level on dobutamine as with placebo. Dobutamine diminished exercise time and 
time to ischemia while peak pressure-rate product was unchanged. Four of 20 patients 
developed complex ventricular premature beats, all while on dobutamine. Although useful when 
administered to resting patients with acute left ventricular failure, dobutamine’s effects may be 
deleterious in exercising patients with chronic ischemic heart disease. (AM HEART J 107:81, 
1984.) 
Mark A. Rabinovitch, M.D., Victor Kalff, M.D., William Chan, M.D., 
Anthony Schork, Ph.D., Milton D. Gross, M.D., Robert A. Vogel, M.D., 
James H. Thrall, M.D., and Bertram Pitt, M.D. Ann Arbor, Mich. 
Dobutamine is a positive inotropic agent with a 
predominant action on beta-1-adrenergic receptors 
and a relatively weak chronotropic effect.’ It has 
found wide use in patients with ischemic and nonis- 
chemic ventricular failure.2-5 Dobutamine’s use in 
patients with acute ischemic left ventricular failure 
is supported by experimental studies showing that it 
may maintain or improve coronary blood flow to 
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ischemic or potentially ischemic areas of myocardi- 
um.6s 7 
It would also be of interest to know what effects 
dobutamine has on left ventricular performance 
during exercise in patients with ischemic heart 
disease. For example, if dobutamine improves the 
myocardial oxygen supply-demand ratio in this set- 
ting, then its intermittent infusion could be useful in 
conjunction with exercise in postmyocardial infarc- 
tion patients undergoing cardiac rehabilitation.s 
The present study was therefore designed to assess 
dobutamine’s effect on exercise performance in a 
group of patients with chronic ischemic heart dis- 
ease (CAD) and a wide range of resting left ventric- 
ular function. 
METHODS 
Patients. Twenty ambulatory patients with ischemic 
heart disease were studied after giving informed consent. 
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Fig. 1. Illustration of the effect of dohutamine on the 
ejection fraction at rest and during exercise. The solid 
lines represent the response to placebo, the dashed lines 
the response to dobutamine. L VEF = left ventricular ejec- 
tion fraction; R = resting; Ex Submax = submaximal 
exercise, Ex Max = maximal exercise. *p < 0.01. 
There were 18 men and two women and their mean age 
was 56 years (range 34 to 81). Coronary artery disease was 
proved in 17 cases by catheterization, and presumed in 
two with classic angina and segmental wall motion defects 
on exercise radionuclide ventriculography and in one with 
angina pectoris following two documented myocardial 
infarctions. Of the catheterization-proved cases, 10 had 
triple-vessel disease, six had double-vessel disease, and 
one had single-vessel disease. Eighteen patients had clas- 
sic angina pectoris and 13 had well-documented previous 
myocardial infarctions. All 20 had exercise-induced ische- 
mia as revealed by exercise ECG and/or rest-exercise 
radionuclide ventriculography. No patient was studied 
within 6 weeks of a myocardial infarction and patients 
with significant valvular disease were excluded. All 
patients were in functional class II or III of the New York 
Heart Association, and none had clinically uncompen- 
sated congestive failure at the time of the study. 
Testing. All beta-adrenergic-blocking agents and other 
sympatholytics were discontinued at least 72 hours prior 
to testing and all long-acting nitrates were stopped at least 
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Table I. Resting hemodynamics of study group 
EF HR AP systolic 
Mean i SD 4” rf- 15 77 + 14 133 + 16 
Range 22 - 68 55 - 102 110- 165 
Abbreviations: EF = ejection fraction; HR = heart rate; AP = arterial pres- 
sure. 
12 hours beforehand. Two intravenous solutions, one 
containing placebo (dextrose and water) and the other 
containing dobutamine (5 Mg/kg/min infusion via Harvard 
pump), were prepared by the hospital pharmacy and 
labeled randomly as solutions A and B. Each patient then 
underwent supine, multiple, gated rest-exercise radionu- 
elide ventriculography.“’ First, baseline resting images 
were obtained in the left anterior oblique (LAO) and 
lo-degree right anterior oblique (RAO) projections. Then 
infusion of solution A was commenced and 3 minutes later 
repeat LAO and lo-degree RAO images were obtained. 
While the infusion of solution A continued, each patient 
performed a symptom-limited exercise protocol consisting 
of 4-minute stages at standardized incremental work 
loads. Images were obtained at each level of exercise in the 
LAO view. A final lo-degree RAO image was acquired at a 
submaximal exercise load (25 watt-seconds less than 
peak). After at least 1 hour of recuperation, each patient 
underwent identical rest-exercise radionuclide ventricu- 
lography, but with solution B instead of A. Heart rate, 
blood pressure, and the CM 5 ECG lead were monitored 
throughout each study. 
Data analysis. The following exercise parameters were 
measured in each patient for both the dobutamine and 
placebo exercise periods: (1) peak work load completed, 
(2) exercise time, (3) time to angina, (4) time to significant 
ST depression defined as 21 mm of horizontal or down- 
sloping depression below baseline in the absence of digi- 
talis therapy, (5) time to ischemia defined as the time to 
onset of angina or ST depression, whichever came first, 
and (6) development of significant ventricular ectopy (> 10 
ectopics/min, ~2 foci, couplets, ventricular tachycardia). 
The following hemodynamic and ventriculographic 
parameters were measured in each patient for both the 
dobutamine and placebo exercise periods: (1) heart rate, 
(2) systemic arterial pressure, (3) pressure-rate product 
defined as systolic pressure x heart rate/RX), (4) left 
ventricular ejection fraction determined by computer- 
assisted analysis of the left ventricular time-activity curve 
with the use of commercially available software (A’ Medi- 
cal Data Systems), (5) count-based end-diastolic and 
end-systolic relative volumes,” and (6) segmental wall 
motion analysis. Briefly, decay and background-corrected 
count rates were calculated from the left ventricular 
region of interest of the end-diastolic and end-systolic 
frames for each LAO image. Taking the resting baseline 
count rate to be loo%, the percentages of change in 
end-diastolic and end-systolic count rates were calculated 
for the dobutamine and placebo infusions and for each 
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Table II. Hemodynamic effects of dobutamine (% change from control) 
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Abbreviations: D = dobutamine; PL = placebo; HR = heart rate; AP = systemic arterial pressure; PRP = pressure-rate product (HR X AP systolic/lOO); 
EF = ejection fraction. The change in EF is expressed as a “;# from control (e.g., EF 30”~ - 50 ‘cl gwes a 67 % change). 
*Bonferroni experimentwise p value. 
exercise level. These were expressed as percentage of 
change in end-diastolic volume and percentage of change 
in end-systolic volume. The anterobasal, anterolateral, 
and apical segments were analyzed from the RAO projec- 
tion and the inferoapical, posterolateral, and posterobasal 
segments were assessed from the LAO projection. The 
septal segment was excluded from analysis because of 
poor reproducibility of subjective analysis and the dia- 
phragmatic segment was excluded because of frequent 
right ventricular overlap. Wall motion was visually judged 
to be either hyperkinetic (4+), normal (3+), mildly hypo- 
kinetic (2+), severely hypokinetic (l+), akinetic (0), or 
dyskinetic (-1). Worsening of motion in any wall segment 
was defined as a reduction of one or more grades com- 
pared to resting baseline while improvement was defined 
as an increase of one or more grades compared to resting 
baseline. 
Statistical analysis. Absolute resting hemodynamics of 
the study group are expressed as the mean * one stan- 
dard deviation (SD). All other data are expressed as the 
mean + standard error of the mean @EM). Student’s t 
test for paired data was used to determine the significance 
of the differences between all exercise, hemodynamic, and 
ventriculographic parameters during placebo and dobu- 
tamine administration. Hemodynamic and ventriculo- 
graphic parameters were compared at rest, submaximal 
exercise (one stage below peak), and maximal exercise. 
Experimentwise, LY errors using Bonferroni’s method were 
used to assess significance for each exercise condition 
(rest, submaximal, and maximal). 
RESULTS 
Hemodynamics. The baseline resting hemodynam- 
its of the study groups are listed in Table I. The 
hemodynamic effects of dobutamine at rest are 
summarized in Table II. Dobutamine increased rest- 
ing heart rate, systolic blood pressure, pressure-rate 
product, and resting left ventricular ejection frac- 
tion. Two patients had a decrease in left ventricular 
ejection fraction on dobutamine infusion before 
exercise. In one patient, the ejection fraction fell 
from 68% to 54% with the appearance of a new wall 
motion abnormality. The other patient had a 
decrease in left ventricular ejection fraction from 
30 % to 22 % on dobutamine before exercise. 
Twelve of the 20 patients were able to perform an 
intermediate (submaximal) level of exercise prior to 
the development of symptoms. The hemodynamic 
effects of dobutamine during submaximal exercise 
in these 12 patients are shown in Table II. The 
increases in heart rate, systolic arterial pressure, and 
pressure-rate prdouct were similar on dobutamine 
and placebo. Concurrently, left ventricular ejection 
fraction remained higher while patients were on 
dobutamine. The hemodynamic effects of dobuta- 
mine during maximal exercise for the study popula- 
tion are also shown in Table II. Peak heart rate, 
systolic arterial pressure, and pressure-rate product 
increased by approximately the same amount on 
dobutamine and placebo while the fall in left ven- 
tricular ejection fraction was similar for dobutamine 
and placebo. 
Comparison of the ejection fraction responses on 
dobutamine and placebo is depicted in Fig. 1. Ejec- 
tion fraction rose with dobutamine at rest. Although 
ejection fraction fell with dobutamine during sub- 
maximal exercise, it remained higher than with 
placebo. At peak exercise, ejection fraction fell to 
the same level as with placebo. Dobutamine caused 
improved motion in a notable percentage of wall 
segments at rest and submaximal exercise compared 
with placebo. By peak exercise, few improved seg- 
ments remained on either infusion. Approximately 
the same percentage of segments worsened during 
exercise with dobutamine and placebo. Although 
relative end-diastolic and end-systolic volume 
tended to be smaller on dobutamine than on place- 
bo, the differences were not statistically signifi- 
cant. 
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Table III. Effects of dobutamine on exercise tolerance 
Er time Peak work 







D 6.7 f 0.8 51 2 6 4.3 t 0.7 3.8 + 0.7 
PI 8.7 * 1.1 63 f 7 6.2 k 1.1 5.5 i 1.1 
p* NS -Co.05 NS NS 
Abbreviations: Ex = exercise; min = minutes; W-S = watt-seconds; other 
abbreviations as in Table II. 
‘Bonferroni experiment&e p value. 
Exercise performance. Dobutamine’s effects on 
measurements of exercise tolerance are summarized 
in Table III. While dobutamine produced a curtail- 
ment in total exercise time, time to angina, and time 
to ischemia, only a reduction in peak work load 
achieved a statistically significant keduction. Exer- 
cise time, peak work load achieved, and time to 
ischemia were the same or shorter on doubtamine in 
19 out of the 20 patients. Only one patient demon- 
strated improved exercise tolerance on dobutamine. 
Although no patient in this series sustained ventric- 
ular tachycardia, four developed lower grades of 
ventricular ectopy on dobutamine which did not 
appear on placebo. 
DISCUSSION 
Despite a decade of investigation, controversy 
continues to surround the use of dobutamine in the 
setting of myocardial ischemia. Tuttle and Mills’ 
synthesized dobutamine in an attempt to minimize 
isoproterenol’s potent chronotropic, arrhythmogen- 
ic, and peripheral vascular effects. They docu- 
mented that these properties, which made the use of 
isoproterenol hazardous in the context of myocardi- 
al ischemia, were greatly attenuated with dobuta- 
mine.’ They postulated that dobutamine’s ability to 
increase myocardial oxygen consumption by increas- 
ing contractility would be offset by a reduction in 
ventricular volume and thus wall tension. They also 
predicted that because of its strong inotropic action 
and attenuated chronotropic and beta-2 stimulatory 
effects, dobutamine should actually improve coro- 
nary blood flow to an ischemic region and limit the 
extent of infarction. This hypothesis has been tested 
in several animal models and the results were found 
to be variable, in part depending upon the degree of 
tachycardia induced by dobutamine.‘j, 12-** 
Previous studies. Results in patients with ischemic 
heart disease have also been variable. Gillespie et al2 
administered dobutamine in doses of 1 to 40 pg/ 
kg/min for 24 hours, so as to avoid an excessive 
increase in heart rate, in 16 patients with evolving 
acute myocardial infarction and impaired left ven- 
tricular function. Dobutamine improved left ven- 
tricular performance without evoking myocardial 
ischemia or arrhythmias. Recently, the effects of 
dobutamine in chronic ischemic heart disease have 
been explored. In doses of 2.5 to 10 pg/kg/min, 
Bendersky et a1.15 found that dobutamine could 
improve left ventricular function without evoking 
myocardial ischemia in seven of eight patients with 
chronic ischemic heart failure. Pozen et a1.16 admin- 
istered dobutamine to 18 patients with ischemic 
heart disease and a history of congestive heart 
failure by using a protocol of incremental infusion of 
dobutamine from 2.5 to 15 pg/kg/min.16 Four 
adverse metabolic responders were identified on the 
basis of lactate extraction, three of whom developed 
angina pectoris. It is probable that any salutary 
effect of dobutamine was overbalanced by its oxy- 
gen-wasting effects in these four patients. 
Present study. The present study demonstrates 
that dobutamine reduces exercise capacity in 
patients with ischemic heart disease over a wide 
range of resting left ventricular function. The fact 
that the time to exercise-induced ischemia was 
shorter for patients on dobutamine while peak pres- 
sure-rate product was the same suggests that a 
critical level of myocardial oxygen consumption was 
reached earlier while patients were on dobutamine. 
The patients did, however, maintain a significant- 
ly higher left ventricular ejection fraction during 
submaximal exercise on dobutamine compared with 
placebo. On the surface, this result appears at odds 
with the reduced exercise capacity of patients on 
dobutamine. The analysis of segmental left ventric- 
ular function, albeit qualitative, provides an expla- 
nation. At rest, dobutamine improved a large num- 
ber of myocardial segments which were either 
hypokinetic or normokinetic. However, during sub- 
maximal and maximal exercise, there were as many 
deteriorated segments on dobutamine compared 
with placebo. Therefore, the higher left ventricular 
ejection fraction at submaximal exercise on dobu- 
tamine probably reflected better function of nonis- 
chemic segments rather than any reduction in the 
mass of ischemic myocardium. Furthermore, the 
study group did not have a significant reduction in 
left ventricular volumes on dobutamine at rest or 
during submaximal exercise. It is, therefore, likely 
that any slight reduction in wall tension that might 
have occurred secondary to dobutamine was over- 
shadowed by its oxygen-wasting property. 
Mechanisms. Three factors may have contributed 
to the unfavorable outcome of dobutamine treat- 
ment in the present study. First, despite a relatively 
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low dose of dobutamine of 5 pg/kg/min used in the 
present study, resting heart rate rose significantly. 
This unexpected rise in resting heart rate could not 
be.attributed to a hyperadrenergic state secondary 
to beta blocker withdrawal. There were no signifi- 
cant differences in the hemodynamic response 
(heart rate, systolic arterial pressure, and left ven- 
tricular ejection fraction) in the five patients in 
whom beta blockers had been withdrawn prior to the 
study and the 15 patients who had not been on 
beta-adrenergic blockers. Second, most of the 
patients in the present study who were catheterized 
had multivessel disease (16 of 17) and 10 of 17 had 
triple-vessel disease. The presence of diffuse myo- 
cardial ischemia, as shown in an experimental study 
by Vatner et a1.,17 would be expected to block 
improvement in myocardial contractility and, as a 
result, there would be little, if any, improvement in 
coronary perfusion in the face of increased myocar- 
dial oxygen demands resulting from an increase in 
heart rate and/or wall tension. Third, in the present 
study, mild coronary artery stenoses were present in 
addition to high-grade lesions in several patients. It 
has recently been shown that dobutamine, in addi- 
tion to other beta-receptor stimulators, can produce 
a reduction in coronary perfusion pressure distal to 
such mild &noses resulting in a maldistribution of 
distal coronary blood flow away from the subendo- 
cardium.ls 
Conclusions. This study indicates that dobuta- 
mine may have adverse effects on exercise perfor- 
mance in patients with reversibly ischemic 
myocardium. However, as suggested by the study of 
Bendersky et a&l5 dobutamine might be beneficial in 
patients with compromised left ventricular function 
but little or no remaining reversibly ischemic myo- 
cardium15. The present study suggests caution in the 
use of any inotropic agent in patients with chronic 
ischemic heart disease. Before an inotropic agent 
can be recommended for use in such patients, there 
should be clear demonstration that the balance 
between myocardial oxygen supply and demand, as 
evidenced by exercise tolerance, is improved. An 
improvement in global left ventricular performance, 
as measured by left ventricular ejection fraction, 
may not reflect the effect of the agent on ischemic or 
potentially ischemic areas of myocardium. 
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